ResMed Inc.

ResMed Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, ResMed Inc. has 144.24M shares outstanding.

As of June 30, 2026, ResMed Inc. maintains a current ratio of 3.10, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, ResMed Inc. posted a return on equity (ROE) of 24.27, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 20.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.41, useful for judging operating efficiency across full business cycles. The company generates approximately 9.15M in revenue per employee across its workforce of 10,792.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times ResMed Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ResMed Inc. recorded 6.92B in income tax expense. That works out to an effective tax rate of 20.64, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 33.54B, leaving 26.61B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 13, 2026, ResMed Inc.'s stock has declined approximately 15.68% over the past 52 weeks.

Over the twelve months ended June 30, 2026, ResMed Inc. generated 98.77B in revenue and converted that into 26.61B in net income, yielding earnings per share of 182.30. EBITDA reached 37.23B, while operating income came in at 33.34B.

As of June 30, 2026, ResMed Inc. holds 25.67B in cash and equivalents against 14.43B in total debt, resulting in a net debt position of -14.15B. Total book value stands at 115.06B, with working capital of 51.19B providing operational flexibility.

ResMed Inc. produced 31.55B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.10B in capital expenditures, free cash flow totaled 28.46B - equivalent to 195.55 per share.

Over the twelve months ended June 30, 2026, ResMed Inc. posted a gross margin of 61.06, reflecting its pricing power and cost economics. The operating margin of 33.76 and net profit margin of 26.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, ResMed Inc. paid dividends of 41.98 per share. The dividend payout ratio of 22.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

ResMed Inc.'s most recent stock split took place on August 31, 2010 with a 1:2 split ratio.